A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

NCT05398445 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

769

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Rocatinlimab
DRUG: Placebo

Sponsor

Amgen